InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,719.06
(
-0.27%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 226

Sunday, 07/01/2018 12:51:11 PM

Sunday, July 01, 2018 12:51:11 PM

Post# of 438
EYEN has a pioneering precision ophthalmology dosing technology that could disrupt eye droppers.

Lead program is a treatment for closed angled glaucoma that will enter Ph3 Q1/19

EYEN is expecting data in 2019 for their pharmacologic dilation program.

They have an OTC artificial tears device that may be ready to market in 2019.

Their program with the greatest commercial potential is their treatment to arrest Myopia. It's entering the clinic in 2019 and is expected to be ready for regulatory submission ins 2022.

Cash runway will take them into Q4/19.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up